Literature DB >> 12529960

Detection of the p110 beta subunit of phosphatidylinositol 3-kinase complexed with neutral endopeptidase.

Ruoqian Shen1, Matthew I Milowsky, Naoko Ozaki, Daniel Navarro, Makoto Sumitomo, Yang Xu, David M Nanus.   

Abstract

BACKGROUND: Neutral endopeptidase 24.11 (NEP) is a cell-surface peptidase that inactivates a variety of neuropeptide substrates. In addition to catalytic activity, NEP can exert biological effects through protein-protein interactions. We previously reported that NEP directly associated with tyrosine-phosphorylated Lyn kinase, and with the p85 subunit of the phosphatidylinositol 3-kinase (PI3 kinase) resulting in an NEP-Lyn-PI3 kinase protein complex.
MATERIALS AND METHODS: In this report, we investigated the association of NEP with cytoplasmic proteins using ProteinChip Array, surface enhanced laser desorption/ionization (SELDI) technology combined with time-of-flight mass spectrometry, as well as immunoprecipitation and Western blottings.
RESULTS: Using immunocapture on the ProteinChip surface, we identified a 122 kDa protein which associates with NEP derived from LNCaP cell lysates which had the identical molecular weight as the beta-subunit of p110 subunit of phosphatidylinositol 3-kinase. The identity of the p110 beta was confirmed by Western blot analysis of NEP and p110 beta immunoprecipitates using monoclonal antibodies specific for NEP and p110 beta.
CONCLUSION: These data confirm the association of phosphatidylinositol 3-kinase (consisting of the p85 adaptor and p110 beta-subunit) with NEP. Furthermore, this work demonstrates the ability of mass spectrometry to identify proteins interacting with NEP and potentially other cell-surface peptidases.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12529960

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  3 in total

Review 1.  Neprilysin inhibition: a new therapeutic option for type 2 diabetes?

Authors:  Nathalie Esser; Sakeneh Zraika
Journal:  Diabetologia       Date:  2019-05-14       Impact factor: 10.122

2.  Neprilysin impedes islet amyloid formation by inhibition of fibril formation rather than peptide degradation.

Authors:  Sakeneh Zraika; Kathryn Aston-Mourney; Peter Marek; Rebecca L Hull; Pattie S Green; Jayalakshmi Udayasankar; Shoba L Subramanian; Daniel P Raleigh; Steven E Kahn
Journal:  J Biol Chem       Date:  2010-04-16       Impact factor: 5.157

3.  Neprilysin deficiency protects against fat-induced insulin secretory dysfunction by maintaining calcium influx.

Authors:  Sakeneh Zraika; Duk-Su Koh; Breanne M Barrow; Bao Lu; Steven E Kahn; Sofianos Andrikopoulos
Journal:  Diabetes       Date:  2013-01-17       Impact factor: 9.461

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.